Chapter 8: Future directions for chronic kidney disease research and treatment

Experts discuss personal opinions of areas for future research of chronic kidney disease (CKD) and the use of sodium glucose cotransporter-2 (SGLT2) inhibitor treatment, including use in those who do not fit US Food and Drug Administration (FDA)-approved indications and patient subgroups who were not included in the reviewed studies.

← Back to Conversations with Leaders: CKD